Completed PHASE2 INTERVENTIONAL 3-arm NCT01622348

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Sponsor: Idera Pharmaceuticals, Inc.

Conditions Actively Extending Plaque Psoriasis Moderate to Severe Plaque Psoriasis

Interventions IMO-3100 at 0.16 mg/kg IMO-3100 at 0.32 mg/kg Saline for Injection

Updated 7 times since 2017 Last updated: Dec 12, 2017 Started: May 31, 2012 Primary completion: Nov 30, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01622348, this PHASE2 trial focuses on Actively Extending Plaque Psoriasis and Moderate to Severe Plaque Psoriasis and remains completed. Sponsored by Idera Pharmaceuticals, Inc., it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Dec 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Idera Pharmaceuticals, Inc.

Data source: Idera Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alpharetta, United States , Boston, United States , College Station, United States , Jacksonville, United States , Johnston, United States , Louisville, United States , Macon, United States , Plainfield, United States , Portland, United States , Salt Lake City, United States and 2 more locations